Charles Barnet Nemeroff

7148027, Dec 12, 2006

Feb 25, 2003

10/374288

Michael J. Owens - Lawrenceville GA, US
Charles B. Nemeroff - Atlanta GA, US

Emory University - Atlanta GA

G01N 33/53

435 72, 435 721, 435 723

A method of measuring the individual response to antidepressant drug therapy on the transport inhibition of monoamine neurotransmitters involves in vitro monitoring of radiolabeled monoamine neurotransmitter transport into cells transfected with transport proteins similar to those on neural cells of the individual being studied. The transport occurs in unbuffered serum of the individual who is undergoing or will later undergo pharmaceutical treatment for depression or other neuropsychiatric disorders. The use of buffers is avoided so that the sensitive balance of bound/free drug within the individuals serum is not disrupted prior to or during testing.

8551996, Oct 8, 2013

Mar 12, 2010

13/201485

Jeff Stehouwer - Atlanta GA, US
Mark Goodman - Atlanta GA, US
Clint Kilts - Little Rock AR, US
Charles Nemeroff - Coconut Grove FL, US

Emory University - Atlanta GA

A61K 31/4985
C07D 471/04

514249, 544336, 544350, 514247

Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e. g. , corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e. g. , labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e. g.

20020160056, Oct 31, 2002

Apr 22, 2002

10/127257

Charles Nemeroff - Atlanta GA, US
Clinton Kilts - Atlanta GA, US

A61K033/00
A61N001/30

424/722000, 604/020000

A method and device for treating acute mania or bipolar disorder is disclosed, by transdermal delivery of Li at substantially constant rate through the skin via a dermal patch.

20130287687, Oct 31, 2013

Apr 30, 2013

13/873277

EMORY UNIVERSITY - , US
Mark M. Goodman - Atlanta GA, US
Clint Klits - Atlanta GA, US
Charles Nemeroff - Atlanta GA, US

C07D 471/04
C07D 471/14
C07F 7/22
A61K 51/04

424 189, 544350, 514249, 540578, 51421402, 540476, 514250, 544225, 514185, 424 181, 424 185

The present disclosure relates to organic chemistry and in particular to a series of corticotropin releasing factor type-1 (CRF) receptor ligand compounds and compositions, as well as methods of preparation and treatment.

6375990, Apr 23, 2002

May 24, 2000

09/529248

Charles B. Nemeroff - Atlanta GA
Clinton D. Kilts - Atlanta GA

Emory University - Atlanta GA

A61K 3336

424667

A method and device for treating acute mania or bipolar disorder is disclosed, by transdermal delivery of Li at substantially constant rate through the skin via a dermal patch.

20140179919, Jun 26, 2014

Feb 26, 2014

14/191201

Jeff Stehouwer - Atlanta GA, US
Mark M. Goodman - Atlanta GA, US
Clint Klits - Little Rock AR, US
Charles Nemeroff - Atlanta GA, US

EMORY UNIVERSITY - Atlanta GA

C07F 7/22
C07D 487/04

544225, 544350

The present disclosure relates to organic chemistry and in particular to a series of corticotropin releasing factor type-1 (CRF) receptor ligand compounds and compositions, as well as methods of preparation and treatment.